Abstract
BackgroundSARS-CoV-2 has spread worldwide and poses a great threat to human health. Among COVID-19 patients, those with hypertension have been reported to have higher morbidity and mortality. This study was conducted to provide the international community with a deeper understanding of COVID-19 with hypertension.MethodsA total of 623 COVID-19 patients enrolled in Wuhan’s hospital were studied from January to March 2020. The epidemiology, clinical features, and laboratory data of hypertensive patients with COVID-19 were collected, retrospectively analyzed, and compared with a normotensive group. The use of antihypertensive drugs, general treatment, and clinical outcomes of hypertensive patients were also analyzed.ResultsThe median ages in hypertensive patients with mild and severe COVID-19 were both significantly greater than the median age in the normotensive group. But there was no significant gender difference between the hypertensive and normotensive groups. All patients had lived in Wuhan area. Common symptoms of all patients included fever, cough, and fatigue. Chest computed tomography (CT) scans showed bilateral patchy shadows or ground glass opacity in the lungs of all patients. All (315 (100%)) of the hypertensive patients received antiviral therapy (Umifenovir was used alone or in combination with Ribavirin), antibiotic therapy (215 (68.3%)), and corticosteroids (118 (37.5%)). The results suggest that the combination of Umifenovir and Ribavirin as initial therapy for hypertensive patients with COVID-19 is effective and safe. There were no significant differences in laboratory data between the mild cases in the hypertensive and the normotensive groups. In the severe cases, the hypertensive patients had higher plasma levels of D-dimer, C-reactive protein (CRP), and Interleukin-6 (IL-6) (P < 0.05). Furthermore, the hypertensive patients who were treated with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) were not represented in a statistically significant manner between the mild and severe groups (p > 0.05).ConclusionIn this study, we demonstrated that the hypertensive patients who were treated with ACEI/ARB did not have an increased risk of developing severe COVID-19. Umifenovir and Ribavirin played an important role in the treatment of viral pneumonia. Hypertensive patients with severe viral pneumonia had stronger inflammatory responses than nonhypertensive patients.
Highlights
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing a huge survival crisis ofThis work is licensed under the Creative Commons Attribution 4.0368 Shuang wang et al.mankind
In this study, we demonstrated that the hypertensive patients who were treated with ACEI/ARB did not have an increased risk of developing severe COVID-19
The enrolled 315 hypertensive patients and 308 nonhypertensive patients were all confirmed infected with COVID-19 using PCR tests of throat swabs
Summary
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing a huge survival crisis ofThis work is licensed under the Creative Commons Attribution 4.0368 Shuang wang et al.mankind. Human pathogenic coronaviruses (severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2) bind to their target cells through angiotensin-converting enzyme 2 (ACE2) receptor, which is expressed by epithelial cells of the lung, intestine, kidney, and blood vessels [5]. The function of this enzyme is to catalyze the conversion of angiotensin II to angiotensin 1–7, a peptide that opposes the pro-inflammatory, prooxidative, vasoconstrictive, and fibrotic properties of angiotensin II [6]. Severe cases have been shown to develop into acute respiratory distress syndrome (ARDS) and other serious complications, eventually leading to multiple organ failure
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
